The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer

Estrogen receptor-α (ERα)-negative breast cancer is clinically aggressive and does not respond to conventional hormonal therapies. Strategies that lead to re-expression of ERα could sensitize ERα-negative breast cancers to selective ER modulators. FTY720 (fingolimod, Gilenya), a sphingosine analog,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hait, N C, Avni, D, Yamada, A, Nagahashi, M, Aoyagi, T, Aoki, H, Dumur, C I, Zelenko, Z, Gallagher, E J, Leroith, D, Milstien, S, Takabe, K, Spiegel, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753524/
https://www.ncbi.nlm.nih.gov/pubmed/26053034
http://dx.doi.org/10.1038/oncsis.2015.16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753524/
https://www.ncbi.nlm.nih.gov/pubmed/26053034
http://dx.doi.org/10.1038/oncsis.2015.16

Ejemplares similares